Cinacalcet as a First-Line Treatment in Neonatal Severe Hyperparathyroidism Secondary to Calcium Sensing Receptor (CaSR) Mutation
暂无分享,去创建一个
H. Bilgen | E. Ozek | A. Bereket | S. Turan | P. Ata | T. Kirkgoz | M. Eltan | Sinem Gulcan-Kersin | Turkay Rzayev
[1] M. Levine,et al. Neonatal severe hyperparathyroidism due to a homozygous mutation of calcium-sensing receptor; a challenging case , 2019, Ceylon Medical Journal.
[2] M. Kul,et al. A rare cause of neonatal hypercalcemia: Neonatal severe primary hyperparathyroidism: A case report and review of the literature , 2019, International journal of surgery case reports.
[3] S. Marx,et al. Neonatal Severe Hyperparathyroidism: Novel Insights from Calcium, PTH, and the CASR Gene. , 2019, The Journal of clinical endocrinology and metabolism.
[4] C. Gorvin. Molecular and clinical insights from studies of calcium-sensing receptor mutations. , 2019, Journal of molecular endocrinology.
[5] A. Niemi,et al. Cinacalcet therapy in an infant with an R185Q calcium-sensing receptor mutation causing hyperparathyroidism: a case report and review of the literature , 2019, Journal of pediatric endocrinology & metabolism : JPEM.
[6] Y. Tao,et al. Novel homozygous inactivating mutation of the calcium-sensing receptor gene in neonatal severe hyperparathyroidism responding to cinacalcet therapy , 2018, Medicine.
[7] M. Accadia,et al. Case report: acute clinical presentation and neonatal management of primary hyperparathyroidism due to a novel CaSR mutation , 2018, BMC Pediatrics.
[8] T. Tsukamoto,et al. The use of cinacalcet hinders the diagnosis of parathyroid carcinoma in a chronic dialysis patient: a case report , 2017, BMC Nephrology.
[9] A. Al-Zahrani,et al. Neonatal severe hyperparathyroidism secondary to a novel homozygous CASR gene mutation. , 2017, Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases.
[10] Erdal Kurnaz,et al. Treatment experience and long-term follow-up data in two severe neonatal hyperparathyroidism cases , 2016, Journal of pediatric endocrinology & metabolism : JPEM.
[11] A. Vargas,et al. Neonatal severe hyperparathyroidism caused by homozygous mutation in CASR: A rare cause of life-threatening hypercalcemia. , 2016, European journal of medical genetics.
[12] M. M. Fisher,et al. Successful treatment of neonatal severe hyperparathyroidism with cinacalcet in two patients , 2015, Endocrinology, diabetes & metabolism case reports.
[13] G. Hendy,et al. Novel homozygous inactivating mutation of the calcium-sensing receptor gene (CASR) in neonatal severe hyperparathyroidism-lack of effect of cinacalcet. , 2014, Bone.
[14] M. Levine,et al. Cinacalcet monotherapy in neonatal severe hyperparathyroidism: a case study and review. , 2014, The Journal of clinical endocrinology and metabolism.
[15] E. García Soblechero,et al. Neonatal Hypercalcemia due to a Homozygous Mutation in the Calcium-Sensing Receptor: Failure of Cinacalcet , 2013, Neonatology.
[16] E. Girardin,et al. Successful Use of Bisphosphonate and Calcimimetic in Neonatal Severe Primary Hyperparathyroidism , 2012, Pediatrics.
[17] G. Hendy,et al. Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet. , 2011, The Journal of clinical endocrinology and metabolism.
[18] D. Cole,et al. Neonatal severe hyperparathyroidism: further clinical and molecular delineation , 2011, European Journal of Pediatrics.
[19] C. M. Haring,et al. Correction of hypercalcaemia by cinacalcet in familial hypocalciuric hypercalcaemia , 2007, Clinical endocrinology.
[20] J. Bilezikian,et al. The role of calcimimetics in the treatment of hyperparathyroidism , 2007, European journal of clinical investigation.
[21] E. Wiltshire,et al. Neonatal Hyperparathyroidism and Pamidronate Therapy in an Extremely Premature Infant , 2007, Pediatrics.
[22] H. Timmers,et al. Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium‐sensing receptor , 2006, Journal of internal medicine.
[23] S. Pearce,et al. Neonatal severe hyperparathyroidism: genotype/phenotype correlation and the use of pamidronate as rescue therapy , 2004, European Journal of Pediatrics.
[24] G. Hendy,et al. Mutations of the calcium‐sensing receptor (CASR) in familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia , 2000, Human mutation.
[25] B. Steinmann,et al. Casting new light on the clinical spectrum of neonatal severe hyperparathyroidism , 1999, Clinical endocrinology.
[26] E. Nemeth,et al. Calcimimetic Compounds: a Direct Approach to Controlling Plasma Levels of Parathyroid Hormone in Hyperparathyroidism , 1999, Trends in Endocrinology & Metabolism.
[27] M. Nakazato,et al. Familial hypocalciuric hypercalcemia associated with mutation in the human Ca(2+)-sensing receptor gene. , 1995, The Journal of clinical endocrinology and metabolism.
[28] M. Hediger,et al. Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid , 1993, Nature.
[29] H. Wilkinson,et al. Self limiting neonatal primary hyperparathyroidism associated with familial hypocalciuric hypercalcaemia. , 1993, Archives of disease in childhood.
[30] S. Harris,et al. Neonatal hyperparathyroidism: the natural course in the absence of surgical intervention. , 1989, Pediatrics.
[31] J. Haddow,et al. Self-limited neonatal hyperparathyroidism in familial hypocalciuric hypercalcemia. , 1987, Jornal de Pediatria.